Compare Boston Scientific Corporation (BSX) vs Simon Property Group Inc (SPG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs Simon Property Group Inc — how do they compare? Boston Scientific Corporation trades at $51.08 (market cap $74.19B), while Simon Property Group Inc trades at $220.3 (market cap $71.03B). The key difference: Boston Scientific Corporation and Simon Property Group Inc are close in size by market cap, and Simon Property Group Inc pays a 4.05% dividend while Boston Scientific Corporation pays none. Which is the better fit depends on your goals.
| BSX | SPG | |
|---|---|---|
Market Cap | $74.19B | $71.03B |
Sector | Health | Real Estate |
52-Week High | $108.14 | $236.70 |
52-Week Low | $42.63 | $169.22 |
Enterprise Value | $86.27B | $99.48B |
Dividend Yield | — | 4.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BSX trades at $50.46, up 2.33% today, with strong earnings beats in recent quarters and a bullish technical trend. Revenue grew to $20.07B in 2025, with net income margin expanding to 17.5%. The stock shows robust institutional support and insider buying, while facing near-term headwinds from competitive pressures in key segments like WATCHMAN.
Outlook remains positive with 86% analyst buy ratings and a $67.21 consensus price target, implying 33% upside. Risks include guidance cuts and market share losses, but solid cash flow and valuation metrics support long-term growth potential for patient investors.
SPG trades at $220.55, down 1.06% with a bearish technical signal. The REIT shows strong fundamentals with Q2 2026 FFO beating estimates at $3.29 per share and raised full-year guidance. Valuation metrics appear reasonable with P/E of 15.49 and EV/EBITDA of 11.96, while profitability remains robust with 66.57% net margin and 135.7% ROE. Recent news highlights leasing strength and retailer sales growth driving performance.
The outlook remains positive with analyst consensus at Buy (40.54%) and $226.58 price target offering 2.7% upside. Key risks include interest rate sensitivity from $24.21B debt load and retail sector headwinds. Strong cash flow generation and dividend consistency support the investment case for income-focused investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About Simon Property Group Inc
Simon Property Group is the second- largest real estate investment trust in the United States. Its portfolio includes an interest in 207 properties: 119 traditional malls, 69 premium outlets, 14 Mills centers (a combination of a traditional mall, outlet center, and big-box retailers), six lifestyle centers, and five other retail properties. Simon's portfolio averaged $693 in sales per square foot over the 12 months prior to the pandemic. The company also owns a 21% interest in Klepierre, a European retail company with investments in shopping centers in 16 countries, and joint venture interests in 33 premium outlets across 11 countries.
Read more on SPG →
